Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

64.42USD
20 Oct 2017
Change (% chg)

$-0.25 (-0.39%)
Prev Close
$64.67
Open
$64.79
Day's High
$64.99
Day's Low
$64.21
Volume
2,200,802
Avg. Vol
1,632,884
52-wk High
$66.09
52-wk Low
$46.01

Select another date:

Mon, Oct 16 2017

BRIEF-FDA accepts Bristol-Myers Squibb’s application for Opdivo

* U.S. Food and Drug Administration (fda) accepts Bristol-Myers Squibb’s application for Opdivo (nivolumab) in patients with resected high-risk advanced melanoma and grants priority review Source text for Eikon: Further company coverage:

BRIEF-Bristol-Myers ‍announces data for Opdivo and Opdivo plus Yervoy in previously treated small cell lung cancer​

* Bristol-Myers Squibb Co ‍announced data evaluating Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in previously treated small cell lung cancer​

BRIEF-Bristol-Myers Squibb extends strategic partnership with Target Pharmasolutions

* Says BMY extended strategic partnership for TARGET-NASH to multi-year agreement​

BRIEF-Bristol-Myers Squibb names Saurabh Saha as senior vice president

* Bristol-Myers Squibb appoints Saurabh Saha, M.D., Ph.D., as senior vice president, global head of translational medicine Source text for Eikon: Further company coverage:

BRIEF-Exelixis to receive milestone payment from Bristol-Myers Squibb

* Exelixis to receive milestone payment from Bristol-Myers Squibb for submission of clinical trial authorization for RORγt inverse agonist program

BRIEF-Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration

* Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration evaluating ipi-549 in combination with Opdivo (nivolumab)

BRIEF-AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors

* AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors

BRIEF-Japanese ministry of Health, Labor and Welfare approves Opdivo for treatment of unresectable advanced or recurrent gastric cancer

* Bristol-Myers Squibb - Japanese Ministry of Health, Labor and Welfare has approved Opdivo for treatment of unresectable advanced or recurrent gastric cancer Source text for Eikon: Further company coverage:

UK backs Opdivo for lung cancer after Bristol-Myers cuts price

LONDON Bristol-Myers Squibb's immunotherapy drug Opdivo has been recommended for some patients with lung cancer by Britain's healthcare cost watchdog NICE after the drugmaker agreed a discounted price.

UK backs Opdivo for lung cancer after Bristol-Myers cuts price

LONDON, Sept 20 Bristol-Myers Squibb's immunotherapy drug Opdivo has been recommended for some patients with lung cancer by Britain's healthcare cost watchdog NICE after the drugmaker agreed a discounted price.

Select another date: